Pharma BD Deal Intelligence

Ciba-Geigy AG / Sandoz AG

1996 · Acquisition/Merger · $36.3B · Complete

Announcement Sentiment

Neutral / mixed

Outcome Score

Worked — the deal delivered on its rationale.

Ciba-Geigy and Sandoz merged in a deal valued at approximately $36.3 billion to create Novartis, the world's second-largest pharmaceutical company at the time. The merger of equals combined two diversified Swiss chemical and pharmaceutical conglomerates.

Key facts

Announced Mar 07, 1996
Closed Dec 20, 1996
Deal value $36.3B
Deal type Acquisition/Merger
Therapeutic area Dermatology, Immunology, Neurology, Oncology, Ophthalmology
Indications Organ Transplant Rejection, Inflammation, Schizophrenia
Key assets Sandimmune/Neoral (cyclosporine), Voltaren (diclofenac), Clozaril (clozapine), Ciba Vision, Sandoz generics
Mechanism Calcineurin inhibitor, COX inhibitor, Atypical antipsychotic

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals